In an analyst note, Larsen estimated the company had about 100,000 GLP-1-related members on its platform by the end of 2024, bringing in about $240 million in annualized revenue
Evidence so far demonstrates that GLP-1 agonists can produce unprecedented results for people trying to achieve weight loss, in some cases enabling patients to lose 15-20% of their body weighttwo to three times the amount achieved with previous medications
A long-acting glucose dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting, in: American Diabetes Association 83rd Annual Scientific Sessions, San Diego, CA, USA, 23 26 June 2023
This includes both your weight change and any side effects you may be experiencing
Work with a medical team for ongoing support
Phase 3 trials are underway, and a realistic approval window is late 2026 at the earliest, more likely 2027